Literature DB >> 2525871

Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease.

J S Silberberg1, D P Rahal, D R Patton, A D Sniderman.   

Abstract

Left ventricular (LV) hypertrophy is common in end-stage renal disease, yet the factors associated with its development are poorly understood. LV mass index was determined by echocardiography in 78 patients who had been treated by dialysis for at least 3 months. A significant relation was evident between anemia and LV hypertrophy. The mean LV mass index was 158 +/- 6 g/m2 (mean +/- standard error) in patients in the lowest quartile of serum hemoglobin and 140 +/- 10, 132 +/- 7 and 120 +/- 8 g/m2 in the second, third and uppermost quartiles, respectively (p = 0.005). This relation persisted after adjusting for systolic blood pressure, treatment mode and suspected coronary artery disease. Forty-eight patients had paired studies. In these, LV mass index increased as hemoglobin decreased (coefficient = -0.81 g/m2/g/liter, p less than 0.025). These data indicate that anemia contributes to the development of LV hypertrophy in patients with end-stage renal disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525871     DOI: 10.1016/0002-9149(89)90462-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Association of echocardiographic abnormalities with mortality in men with non-dialysis-dependent chronic kidney disease.

Authors:  Jason Payne; Smriti Sharma; Dexter De Leon; Jun L Lu; Fregenet Alemu; Rasheed A Balogun; Sandra M Malakauskas; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Nephrol Dial Transplant       Date:  2011-05-25       Impact factor: 5.992

2.  Recurrent nonsuppressible secondary hyperparathyroidism following subtotal parathyroidectomy.

Authors:  F L Polsky; M A Fullmer
Journal:  West J Med       Date:  1994-05

3.  The effects of iron deficiency anemia on p wave duration and dispersion.

Authors:  Hakki Simsek; Yilmaz Gunes; Cengiz Demir; Musa Sahin; Hasan Ali Gumrukcuoglu; Mustafa Tuncer
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

Review 4.  Recombinant erythropoietin in clinical practice.

Authors:  T Ng; G Marx; T Littlewood; I Macdougall
Journal:  Postgrad Med J       Date:  2003-07       Impact factor: 2.401

5.  Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease.

Authors:  G R Martin; J R Ongkingo; M E Turner; E S Skurow; E J Ruley
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

6.  Increased left main coronary artery dimensions in children with sickle cell disease.

Authors:  Arpan R Doshi; Linda B Pauliks
Journal:  Pediatr Cardiol       Date:  2012-11-28       Impact factor: 1.655

7.  Erythropoietin use and abuse.

Authors:  M Joseph John; Vineeth Jaison; Kunal Jain; Naveen Kakkar; Jubbin J Jacob
Journal:  Indian J Endocrinol Metab       Date:  2012-03

8.  Anemia and hemoglobin serum levels are associated with exercise capacity and quality of life in chronic obstructive pulmonary disease.

Authors:  Marcello Ferrari; Lorenzo Manea; Kamel Anton; Paola Bruzzone; Mara Meneghello; Francesco Zamboni; Luigi Purgato; Lucia Cazzoletti; Pietro Ferrari; Renato Testi
Journal:  BMC Pulm Med       Date:  2015-05-08       Impact factor: 3.317

9.  The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study.

Authors:  Hiroaki Ogata; Junji Kumasawa; Shingo Fukuma; Masahide Mizobuchi; Eriko Kinugasa; Masafumi Fukagawa; Shunichi Fukuhara; Tadao Akizawa
Journal:  Clin Exp Nephrol       Date:  2017-05-15       Impact factor: 2.801

10.  Changes in blood hemoglobin and blood gases PaO2 and PaCO2 in severe COPD overa three-year telemonitored program of long-term oxygen treatment.

Authors:  Roberto W Dal Negro; Silvia Tognella; Luca Bonadiman; Paola Turco
Journal:  Multidiscip Respir Med       Date:  2012-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.